Story
FDA Stands By Taylor Farms Probe Despite Retracted Cyclospora Test
Summary
The U.S. Food and Drug Administration is defending its investigation into a widespread cyclosporiasis outbreak linked to Taylor Farms, stating its case remains strong despite retracting a positive test result on a lettuce sample.
The U.S. Food and Drug Administration is defending its investigation into a widespread cyclosporiasis outbreak linked to Taylor Farms lettuce, stating its case remains strong despite retracting an initial positive test result. The outbreak has sickened over 1,600 people nationally and has been connected to Yum Brands' (NYSE:YUM) Taco Bell locations.
Investigation Continues Amid Test Retraction
The FDA said Monday that the epidemiological and traceback evidence linking lettuce from Taylor Farms de Mexico to the outbreak remains unchanged. The statement came after the agency first announced a positive test for the cyclospora parasite on a border sample Saturday, only to call it a "false positive" on Sunday following a quality-control review.
Acting FDA Commissioner Kyle Diamantas defended the decision to publicize the initial result, citing the urgency of an outbreak with more than 1,600 cases and ongoing illnesses. "We found it was important to share this actionable public health information," said Acting Deputy Commissioner for Food Donald Prater on a call with reporters.
Outbreak Scope and Restaurant Impact
Cyclosporiasis is an intestinal infection contracted from consuming food or water contaminated with feces. The current outbreak has led to significant public health responses and has impacted consumer behavior.
Ad- In Michigan, health officials reported 6,148 cases linked to the outbreak as of Monday, an increase of 1,146 since Friday.
- The state has recorded 102 hospitalizations, with no deaths reported.
- According to data from Placer.ai, consumer foot traffic at Taco Bell fell 30.9% on Friday compared to its recent day-of-week average. Traffic at Chipotle (NYSE:CMG) and Cava (NYSE:CAVA) was down 6.9% and 4.2%, respectively.
Focus Remains on Epidemiological Evidence
Experts noted that the retracted lab result does not invalidate the broader investigation. Former FDA Commissioner Scott Gottlieb said Monday that the agency's conclusions rely primarily on epidemiological evidence rather than a single test on a recent sample.
"This isn’t the product that was affected - it went into the supply chain three weeks ago," Gottlieb said, explaining that the traceback investigation stands on its own. The FDA confirmed the border test was separate from the main U.S. outbreak investigation.
Read next
More on Stocks
Sumitomo Electric Stock Jumps 6% on Meta Transatlantic Cable Deal
Shares of the Japanese cable maker hit a three-week high after it announced a partnership with Meta and NEC to supply advanced optical fiber for a new high-capacity subsea cable linking the U.S. and France.
Rare Earth Stocks Fall on US-China Truce Extension Despite Persistent Supply Risks
Shares of non-Chinese rare earth producers fell following the extension of a trade truce with Beijing, as the perceived geopolitical risk premium eased. However, ongoing Chinese export controls and upcoming U.S. defense mandates point to continued supply chain pressures.
Qualcomm Shares Climb Over 18% in September on AI and Automotive Growth
Qualcomm (QCOM) has seen its stock price surge more than 18% month-to-date, driven by new on-device AI processor announcements and strong performance in its automotive segment.
US and China Extend Trade Truce to January as Xi Arrives in Washington
The United States and China have agreed to extend a trade truce until January 10, a key development as Chinese President Xi Jinping begins a state visit with President Donald Trump. The summit is expected to focus on stabilizing relations, though major breakthroughs on other issues remain unlikely.